Drug Trial Radar · NCT02570308
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Last checked: Nov 20, 2026Latest source record: Mar 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
146
Actual
Start
Feb 29, 2016
Primary completion
Mar 20, 2020
Study completion Oct 17, 2022
Sponsor
- Lead sponsor
- Immunocore LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
IMCgp100-102 is a Phase I/II study of the weekly intra-patient escalation dose regimen with IMCgp100 as a single agent in participants with metastatic uveal melanoma (mUM). According to this regimen, all participants in the trial received 2 weekly doses of IMCgp100 at a dose level below the identified weekly recommended Phase II dose (RP2D-QW) and then a dose escalation commenced at the third weekly dose at C1D15. The Phase I testing of the intra-patient escalation dosing regimen is designed to achieve a higher exposure and maximal plasma concentration of IMCgp100 after doses at Cycle 1 Day 15 (C1D15) and thereafter.
Conditions
- Uveal Melanoma
Interventions
IMCgp100Drug
Bispecific soluble HLA-A2 restricted gp100-specific T-cell receptor fused to anti-CD3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With a Dose Limiting Toxicity (DLT) in Phase 1Time frame: Up to 49 months
- Objective Response Rate in Phase 2Time frame: Up to 38 months
Locations
26 sites in 5 countries. Site status is shown where the registry gives one.
University California, San Diego Moores Cancer Center
La Jolla, California
The Angeles Clinic and Research Institute - W LA Office
Los Angeles, California
California Pacific Medical Center
San Francisco, California
University of Colorado Denver Anschutz Medical Campus
Aurora, Colorado
Georgetown University - Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia
University of Miami Hospital Clinics/Sylvester Comprehensive Cancer Center
Miami, Florida
H. Lee Moffitt Cancer Center and Research Institute, Inc
Tampa, Florida
The University of Chicago Medical Center
Chicago, Illinois
Washington University, School of Medicine
St Louis, Missouri
Roswell Park Cancer Institute
Buffalo, New York
Columbia University Medical Center - The New York Presbyterian Hospital
New York, New York
Memorial Sloan Kettering Hospital
New York, New York
Dean A. Mcgee Eye Institute
Oklahoma City, Oklahoma
Providence Portland Medical Center
Portland, Oregon
Thomas Jefferson University Medical Oncology Clinic
Philadelphia, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Baylor Scott & White Health
Temple, Texas
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin
Berlin, Germany
Universitaetsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Hospital General Universitario de Valencia
Valencia, Spain
ICO l'Hospitalet - Hospital Duran i Reynals
L'Hospitalet de Llobregat, Barcelona, Spain
The Clatterbridge Cancer Centre
Metropolitan Borough of Wirral, Merseyside, United Kingdom
Mount Vernon Cancer Centre
Northwood, Middlesex, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.